Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035

Overall world revenue for the Viral Vectors and Plasmid DNA Manufacturing Market: In terms of value the market will surpass US$6.0 billion in 2025, the work calculates. The publisher predicts strong revenue growth through to 2035. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Viral Vectors and Plasmid DNA Manufacturing Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Demand for Viral Vector Manufacturing for Gene Therapy R&D and Production is Driving Market Growth

Viral vectors are revolutionising the treatment of rare diseases by enabling highly targeted gene therapy approaches. This cutting-edge technology allows for the delivery of corrected genes directly into a patient's cells, addressing the root cause of genetic disorders rather than just managing symptoms. As gene therapy continues to gain traction, the demand for viral vectors and plasmid DNA has surged, driving rapid growth in the manufacturing sector.

To keep pace, pharmaceutical companies are making substantial investments in production infrastructure. These large-scale initiatives highlight the industry's strong commitment to expanding manufacturing capabilities to support the growing pipeline of gene therapy products.

Stringent Government Regulations Are Hindering Market Growth

Tight regulatory oversight continues to pose a significant barrier to the growth of the viral vector and plasmid DNA manufacturing market, especially as gene therapy gains momentum and demand for these delivery systems rises. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have put in place strict standards to ensure the safety, efficacy, and quality of gene therapies that rely on viral vectors. While these rules are essential to protect patients, they also bring added layers of complexity, cost, and potential delays for manufacturers.

One of the most demanding aspects is compliance with Good Manufacturing Practice (GMP) guidelines, which govern every part of the viral vector production process. Meeting GMP standards requires extensive validation, precise documentation, and robust quality control from start to finish from sourcing raw materials to the final product release. For small biotech firms or newcomers to gene therapy manufacturing, achieving GMP compliance can be both financially and logistically overwhelming. In fact, GMP requirements can push manufacturing costs up by 30-50%, making it harder to advance products through development and into the market. A notable example is Bluebird Bio, which experienced delays in launching its gene therapies due to regulatory hurdles linked to quality control standards.

Moreover, getting regulatory approval for viral vector-based therapies is a lengthy and complicated process. Health authorities demand comprehensive clinical evidence and long-term safety data, which often leads to extended review timelines. This requirement significantly slows down the development and commercialization process, as companies must invest considerable time and resources before moving forward with clinical trials or product launches.

What would be the Impact of US Trade Tariffs on the Global Viral Vectors and Plasmid DNA Manufacturing Market ?

The imposition of U.S. trade tariffs on imported raw materials, bioprocessing equipment, and critical components has increased production costs for domestic manufacturers of viral vectors and plasmid DNA. Many U.S.-based biotech firms rely heavily on global supply chains, particularly for sourcing single-use technologies, specialised enzymes, and cell culture media. When tariffs are applied to these imports, manufacturers either absorb the added costs, reducing profitability, or pass them on to customers, which can make gene therapy development more expensive overall. This is especially challenging for emerging biotech companies and contract development and manufacturing organisations (CDMOs) that operate on tighter margins.

Globally, these tariffs have created dribble effects across the supply chain. International suppliers who traditionally served the U.S. market may seek alternative buyers in Asia or Europe to avoid tariff-related uncertainties. Simultaneously, companies are increasingly diversifying their manufacturing footprints to de-risk operations. This trend has encouraged investment in new manufacturing hubs in regions like Eastern Europe and Southeast Asia, reducing dependency on U.S.-based facilities. As a result, the market is becoming more decentralised, which may benefit global access to gene therapy technologies in the long run but could weaken the U.S.'s dominance in this high-growth sector.

Furthermore, the uncertainty introduced by shifting trade policies has pushed many biomanufacturers to reconsider long-term procurement and localisation strategies. Some U.S. firms are now investing in domestic alternatives to reduce reliance on foreign components, while others are forming joint ventures or entering strategic alliances to secure stable access to critical materials outside tariff zones. While these adjustments may promote greater supply chain resilience, they often involve substantial upfront investment and longer lead times, which can temporarily disrupt innovation cycles. Overall, trade tariffs are reshaping the global viral vector and plasmid DNA landscape by influencing where and how companies choose to produce these essential components.

Key Questions Answered

How is the viral vectors and plasmid DNA manufacturing market evolving?
What is driving and restraining the viral vectors and plasmid DNA manufacturing market?
How will each viral vectors and plasmid DNA manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
How will the market shares for each viral vectors and plasmid DNA manufacturing submarket develop from 2025 to 2035?
What will be the main driver for the overall market from 2025 to 2035?
Will leading viral vectors and plasmid DNA manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
Who are the leading players and what are their prospects over the forecast period?
What are the viral vectors and plasmid DNA manufacturing projects for these leading companies?
How will the industry evolve during the period between 2025 and 2035? What are the implications of viral vectors and plasmid DNA manufacturing projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the viral vectors and plasmid DNA manufacturing market?
Where is the viral vectors and plasmid DNA manufacturing market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the viral vectors and plasmid DNA manufacturing market today, and over the next 10 years:

This 483-page report provides 213 tables and 278 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analysis reveal commercial prospects

In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
You will find original analysis, with business outlooks and developments.
Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.

Segments Covered in the Report

Type

Viral Vectors
Retroviruses
Adenoviruses
Adeno-associated viruses (AAVs)
Lentiviruses
Others
Plasmid DNA

Product and Service

Products
Services

Workflow

Upstream Manufacturing
Vector Amplification/Editing and Expansion
Vector Recovery/Harvesting
Downstream Manufacturing
Purification
Fill Finish

Application

Cell and Gene Therapy
Vaccine Development
Research
Others

Indication

Cancer
Generic Disorders
Infectious Diseases
Others

End-users

Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Russia
Netherlands
Denmark
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Argentina
Colombia
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles for some of the leading companies in the Viral Vectors and Plasmid DNA Manufacturing Market, with a focus on this segment of these companies'operations.

Leading companies profiled in the report

3PBIOVIAN
Addgene
Advanced BioScience Laboratories Inc.
Aldevron
Altogen Biosystems
Amicus Therapeutics
ATUM
Batavia Biosciences B.V.
BioNTech SE
bluebird bio Inc.
Boehringer Ingelheim
Catalent Inc.
Charles River Laboratories
Creative Biogene
Cytiva
FUJIFILM Diosynth Biotechnologies
Genezen
Lonza Group Ltd.
Merck KGaA
Novartis
Recipharm AB
RegenxBio Inc
SK pharmteco
Thermo Fisher Scientific Inc.
uniQure N.V.
VGXI, Inc.
Virovek
VIVEbiotech
Waisman Biomanufacturing
Wuxi AppTec

How will the Viral Vectors and Plasmid DNA Manufacturing Market report help you?

In summary, the 480+ page report provides you with the following knowledge:

Revenue forecasts to 2035 for Viral Vectors and Plasmid DNA Manufacturing Market, with forecasts for type, product and services, workflow, application, indication, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2035 for five regional and 21 key national markets - See forecasts for the Viral Vectors and Plasmid DNA Manufacturing Market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 30 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market.

Find quantitative and qualitative analysis with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analysis, and decisions. This study is for everybody needing commercial analysis for the Viral Vectors and Plasmid DNA Manufacturing Market, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rising Demand for Viral Vectors Manufacturing for the R&D and Production of Gene Therapy Solutions
3.3.1.2 Advancements in Biotechnology, Facilitating Precision Medicine And Innovative Therapies
3.3.1.3 Increasing Investments in Viral Vector Technologies by Biopharmaceutical Companies and CROs
3.3.1.4 Rising Outsourcing of Viral Vector Manufacturing
3.3.2 Market Restraining Factors
3.3.2.1 High Costs Associated with Viral Vector and Plasmid DNA Manufacturing
3.3.2.2 Stringent Government Regulation is Hindering the Market Growth
3.3.2.3 High Cost Associated with Gene & Cell Therapy
3.3.2.4 Challenges Associated with Scaling Up Production While Maintaining Quality and Consistency
3.3.2.5 Intense Competition Among Vendors
3.3.3 Market Opportunities
3.3.3.1 Investments in New Production Facilities and Partnerships To Meet The Growing Demand For Viral Vectors
3.3.3.2 Expanding Applications in the Fields of Regenerative Medicine, Gene Therapy, and Vaccine Development
3.3.3.3 Innovations in Manufacturing Processes
3.4 U.S. Tariffs: What's the Impact on Global Viral Vectors and Plasmid DNA Manufacturing Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.2.5 Timeframe for Recovery
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Market Dynamics and Demand Recovery
3.4.3.4 Policy and Funding Support
3.4.3.5 Timeframe for Recovery
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
3.4.6 Impact of U.S. and China Trade War on Viral Vectors and Plasmid DNA Manufacturing Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Regulatory Framework
3.6 Emerging Markets and Megatrends
3.7 Porter's Five Forces Analysis
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Threat of Substitutes
3.7.5 Threat of New Entrants
3.8 PEST Analysis

4 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Type

4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
4.4 Viral Vectors
4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.4.3 Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
4.4.4 Adeno-Associated Viruses (AAVs)
4.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.4.2 Market Share by Region, 2025 & 2035 (%)
4.4.5 Lentiviruses
4.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.5.2 Market Share by Region, 2025 & 2035 (%)
4.4.6 Adenoviruses
4.4.6.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.6.2 Market Share by Region, 2025 & 2035 (%)
4.4.7 Retroviruses
4.4.7.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.7.2 Market Share by Region, 2025 & 2035 (%)
4.4.8 Others
4.4.8.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.8.2 Market Share by Region, 2025 & 2035 (%)
4.5 Plasmid DNA
4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Product and Service

5.1 Key Findings
5.2 Product and Service Segment: Market Attractiveness Index
5.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
5.4 Product
5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
5.4.2 Market Share by Region, 2025 & 2035 (%)
5.5 Services
5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Workflow

6.1 Key Findings
6.2 Workflow Segment: Market Attractiveness Index
6.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
6.4 Downstream Manufacturing
6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.4.3 Downstream Manufacturing Market Size Estimation and Forecast by Type
6.4.4 Purification
6.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.4.2 Market Share by Region, 2025 & 2035 (%)
6.4.5 Fill Finish
6.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.5.2 Market Share by Region, 2025 & 2035 (%)
6.5 Upstream Manufacturing
6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.5.3 Upstream Manufacturing Market Size Estimation and Forecast by Type
6.5.4 Vector Amplification and Expansion
6.5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.4.2 Market Share by Region, 2025 & 2035 (%)
6.5.5 Vector Recovery/Harvesting
6.5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.5.2 Market Share by Region, 2025 & 2035 (%)

7 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Application

7.1 Key Findings
7.2 Application Segment: Market Attractiveness Index
7.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
7.4 Vaccine Development
7.4.1 Market Size by Region, 2025-2035 (US$ Billion)
7.4.2 Market Share by Region, 2025 & 2035 (%)
7.5 Cell Therapy
7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Gene Therapy
7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
7.6.2 Market Share by Region, 2025 & 2035 (%)
7.7 Antisense & RNAi Therapy
7.7.1 Market Size by Region, 2025-2035 (US$ Billion)
7.7.2 Market Share by Region, 2025 & 2035 (%)
7.8 Others
7.8.1 Market Size by Region, 2025-2035 (US$ Billion)
7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Indication

8.1 Key Findings
8.2 Indication Segment: Market Attractiveness Index
8.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
8.4 Cancer
8.4.1 Market Size by Region, 2025-2035 (US$ Billion)
8.4.2 Market Share by Region, 2025 & 2035 (%)
8.5 Infectious Diseases
8.5.1 Market Size by Region, 2025-2035 (US$ Billion)
8.5.2 Market Share by Region, 2025 & 2035 (%)
8.6 Genetic Disorders
8.6.1 Market Size by Region, 2025-2035 (US$ Billion)
8.6.2 Market Share by Region, 2025 & 2035 (%)
8.7 Others
8.7.1 Market Size by Region, 2025-2035 (US$ Billion)
8.7.2 Market Share by Region, 2025 & 2035 (%)

9 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by End-user

9.1 Key Findings
9.2 End-user Segment: Market Attractiveness Index
9.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-user
9.4 Biotechnology and Biopharmaceutical Companies
9.4.1 Market Size by Region, 2025-2035 (US$ Billion)
9.4.2 Market Share by Region, 2025 & 2035 (%)
9.5 CDMOs
9.5.1 Market Size by Region, 2025-2035 (US$ Billion)
9.5.2 Market Share by Region, 2025 & 2035 (%)
9.6 Academics and Research Institutes
9.6.1 Market Size by Region, 2025-2035 (US$ Billion)
9.6.2 Market Share by Region, 2025 & 2035 (%)
9.7 Others
9.7.1 Market Size by Region, 2025-2035 (US$ Billion)
9.7.2 Market Share by Region, 2025 & 2035 (%)

10 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Region

10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

11.1 Key Findings
11.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
11.3 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
11.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
11.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
11.5.1 North America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
11.6 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
11.7 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
11.7.1 North America Downstream Manufacturing Market Size Estimation and Forecast by Type
11.7.2 North America Upstream Manufacturing Market Size Estimation and Forecast by Type
11.8 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
11.9 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
11.10 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
11.11 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Analysis
11.12 Canada Viral Vectors and Plasmid DNA Manufacturing Market Analysis

12 Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

12.1 Key Findings
12.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
12.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
12.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
12.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
12.5.1 Europe Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
12.6 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
12.7 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
12.7.1 Europe Downstream Manufacturing Market Size Estimation and Forecast by Type
12.7.2 Europe Upstream Manufacturing Market Size Estimation and Forecast by Type
12.8 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
12.9 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
12.10 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
12.11 Germany Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.13 France Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.14 Italy Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.15 Spain Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.16 Russia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.17 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.18 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.19 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

13 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

13.1 Key Findings
13.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
13.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
13.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
13.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
13.5.1 Asia Pacific Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
13.6 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
13.7 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
13.7.1 Asia Pacific Downstream Manufacturing Market Size Estimation and Forecast by Type
13.7.2 Asia Pacific Upstream Manufacturing Market Size Estimation and Forecast by Type
13.8 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
13.9 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
13.10 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
13.11 Japan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.12 China Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.13 India Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.14 Australia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.15 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.16 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

14 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

14.1 Key Findings
14.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
14.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
14.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
14.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
14.5.1 Latin America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
14.6 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
14.7 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
14.7.1 Latin America Downstream Manufacturing Market Size Estimation and Forecast by Type
14.7.2 Latin America Upstream Manufacturing Market Size Estimation and Forecast by Type
14.8 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
14.9 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
14.10 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
14.11 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.12 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.13 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.14 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.15 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

15 MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

15.1 Key Findings
15.2 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
15.3 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
15.4 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
15.5 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
15.5.1 MEA Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
15.6 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
15.7 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
15.7.1 MEA Downstream Manufacturing Market Size Estimation and Forecast by Type
15.7.2 MEA Upstream Manufacturing Market Size Estimation and Forecast by Type
15.8 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
15.9 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
15.10 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
15.11 GCC Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.12 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.13 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

16 Company Profiles

16.1 Competitive Landscape, 2024
16.2 Strategic Outlook
16.3 Lonza Group Ltd.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2020-2024
16.3.3.2 R&D, 2020-2024
16.3.3.3 Regional Market Shares, 2024
16.3.4 Product Benchmarking
16.3.5 Strategic Outlook
16.3.6 SWOT Analysis
16.4 Merck KGaA
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2020-2024
16.4.3.2 R&D, 2020-2024
16.4.3.3 Regional Market Shares, 2024
16.4.4 Product Benchmarking
16.4.5 Strategic Outlook
16.4.6 SWOT Analysis
16.5 uniQure N.V.
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2020-2024
16.5.3.2 R&D, 2020-2024
16.5.3.3 Business Market Shares, 2024
16.5.4 Product Benchmarking
16.5.5 Strategic Outlook
16.6 Catalent Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2020-2024
16.6.3.2 R&D, 2020-2024
16.6.3.3 Business Market Shares, 2024
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.6.6 SWOT Analysis
16.7 Thermo Fisher Scientific Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2020-2024
16.7.3.2 R&D, 2020-2024
16.7.3.3 Regional Market Shares, 2024
16.7.3.4 Business Market Shares, 2024
16.7.4 Product Benchmarking
16.7.5 Strategic Outlook
16.7.6 SWOT Analysis
16.8 Charles River Laboratories
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2020-2024
16.8.3.2 Regional Market Shares, 2024
16.8.4 Product Benchmarking
16.8.5 Strategic Outlook
16.8.6 SWOT Analysis
16.9 FUJIFILM Diosynth Biotechnologies
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Product Benchmarking
16.9.4 Strategic Outlook
16.10 bluebird bio Inc.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2020-2024
16.10.3.2 R&D, 2020-2024
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Aldevron
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Product Benchmarking
16.11.4 Strategic Outlook
16.12 Addgene
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Product Benchmarking
16.12.4 Strategic Outlook
16.13 Creative Biogene
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Product Benchmarking
16.14 VIVEbiotech
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2020-2024
16.14.4 Product Benchmarking
16.14.5 Strategic Outlook
16.15 Recipharm AB
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2020-2024
16.15.4 Product Benchmarking
16.15.5 Strategic Outlook
16.16 Waisman Biomanufacturing
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Product Benchmarking
16.17 VGXI, Inc.
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Product Benchmarking
16.17.4 Strategic Outlook
16.18 Batavia Biosciences B.V.
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Product Benchmarking
16.18.4 Strategic Outlook
16.19 WuXi AppTec
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.1 Financial Analysis
16.19.1.1 Net Revenue, 2020-2024
16.19.1.2 Regional Market Shares, 2024
16.19.1.3 Business Segment Market Shares, 2024
16.19.2 Product Benchmarking
16.19.3 Strategic Outlook
16.20 ATUM
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Product Benchmarking
16.20.4 Strategic Outlook
16.21 Altogen Biosystems
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Product Benchmarking
16.21.4 Strategic Outlook
16.22 GENEZEN
16.22.1 Company Snapshot
16.22.2 Company Overview
16.22.3 Product Benchmarking
16.22.4 Strategic Outlook
16.23 SK pharmteco
16.23.1 Company Snapshot
16.23.2 Company Overview
16.23.3 Financial Analysis
16.23.3.1 Net Revenue, 2020-2024
16.23.4 Product Benchmarking
16.23.5 Strategic Outlook
16.24 Cytiva
16.24.1 Company Snapshot
16.24.2 Company Overview
16.24.3 Product Benchmarking
16.24.4 Strategic Outlook
16.25 Virovek
16.25.1 Company Snapshot
16.25.2 Company Overview
16.25.3 Product Benchmarking
16.25.4 Strategic Outlook
16.26 Advanced BioScience Laboratories Inc. (ABL)
16.26.1 Company Snapshot
16.26.2 Company Overview
16.26.3 Product Benchmarking
16.26.4 Strategic Outlook
16.27 3PBIOVIAN
16.27.1 Company Snapshot
16.27.2 Company Overview
16.27.3 Product Benchmarking
16.27.4 Strategic Outlook
16.28 BioNTech SE
16.28.1 Company Snapshot
16.28.2 Company Overview
16.28.3 Financial Analysis
16.28.3.1 Net Revenue, 2020-2024
16.28.3.2 R&D, 2020-2024
16.28.4 Product Benchmarking
16.28.5 Strategic Outlook
16.29 RegenxBio Inc.
16.29.1 Company Snapshot
16.29.2 Company Overview
16.29.3 Financial Analysis
16.29.3.1 Net Revenue, 2020-2024
16.29.3.2 R&D, 2020-2024
16.29.4 Product Benchmarking
16.30 Novartis
16.30.1 Company Snapshot
16.30.2 Company Overview
16.30.3 Financial Analysis
16.30.3.1 Net Revenue, 2020-2024
16.30.3.2 R&D, 2020-2024
16.30.3.3 Regional Market Shares, 2024
16.30.3.4 Business Segment Market Shares, 2024
16.30.4 Product Benchmarking
16.30.5 Strategic Outlook
16.31 Boehringer Ingelheim International GmbH
16.31.1 Company Snapshot
16.31.2 Company Overview
16.31.3 Financial Analysis
16.31.3.1 Net Revenue, 2020-2024
16.31.3.2 R&D, 2020-2024
16.31.3.3 Regional Market Shares, 2024
16.31.3.4 Business Segment Market Shares, 2024
16.31.4 Product Benchmarking
16.31.5 Strategic Outlook
16.32 Amicus Therapeutics
16.32.1 Company Snapshot
16.32.2 Company Overview
16.32.3 Financial Analysis
16.32.3.1 Net Revenue, 2020-2024
16.32.3.2 R&D, 2020-2024
16.32.4 Product Benchmarking
16.32.5 Strategic Outlook

17 Conclusion and Recommendations

17.1 Concluding Remarks
17.2 Recommendations for Market Players

List of Tables

Table 1 Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
Table 2 Approved Cellular and Gene Therapy Products, 2025
Table 3 Viral Vectors and Plasmid DNA Manufacturing Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 4 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 5 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 6 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 7 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 8 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 9 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 10 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 11 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 12 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 13 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 14 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 15 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 16 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 17 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 18 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 19 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 20 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 21 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 22 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 23 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 24 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 25 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 26 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 27 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 28 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 29 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 30 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 31 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 32 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 33 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 34 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 35 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 36 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 37 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 38 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 40 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 41 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 42 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 43 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 44 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 45 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 46 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 47 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 48 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 49 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 50 North America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 51 North America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 52 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 53 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 54 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 55 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 56 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 57 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 58 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 59 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 60 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 61 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 62 Europe Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 63 Europe Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 64 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 66 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 67 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 68 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 69 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 71 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 72 Russia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 73 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 74 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 76 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 77 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 78 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 79 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 80 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 81 Asia Pacific Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 82 Asia Pacific Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 83 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 84 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 85 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 86 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 87 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 88 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 89 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 90 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 91 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 92 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 93 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 94 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 95 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 96 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 97 Latin America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 98 Latin America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 99 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 100 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 101 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 102 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 103 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 104 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 105 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 106 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 107 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 108 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 109 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 110 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 111 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 112 MEA Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 113 MEA Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 114 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 115 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 116 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 117 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 118 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 119 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 120 Strategic Outlook
Table 121 Lonza Group Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Lonza Group Ltd.: Product Benchmarking
Table 123 Lonza: Strategic Outlook
Table 124 Lonza: SWOT Analysis
Table 125 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Merck KGaA: Product Benchmarking
Table 127 Merck KGaA: Strategic Outlook
Table 128 Merck KGaA: SWOT Analysis
Table 129 uniQure N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 uniQure N.V. : Product Benchmarking
Table 131 uniQure N.V.: Strategic Outlook
Table 132 Catalent Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Catalent Inc.: Product Benchmarking
Table 134 Catalent Inc.: Strategic Outlook
Table 135 Catalent Inc.: SWOT Analysis
Table 136 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Thermo Fisher Scientific Inc.: Product Benchmarking
Table 138 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 139 Thermo Fisher Scientific Inc.: SWOT Analysis
Table 140 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Charles River Laboratories: Product Benchmarking
Table 142 Charles River Laboratories: Strategic Outlook
Table 143 Charles River Laboratories: SWOT Analysis
Table 144 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 FUJIFILM Diosynth Biotechnologies: Product Benchmarking
Table 146 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
Table 147 bluebird bio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 148 bluebird bio Inc.: Product Benchmarking
Table 149 bluebird bio Inc.: Strategic Outlook
Table 150 Aldevron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 Aldevron: Product Benchmarking
Table 152 Aldevron: Strategic Outlook
Table 153 Addgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 154 Addgene: Product Benchmarking
Table 155 Addgene: Strategic Outlook
Table 156 Creative Biogene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 157 Creative Biogene: Product Benchmarking
Table 158 VIVEbiotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 VIVEbiotech: Product Benchmarking
Table 160 VIVEbiotech: Strategic Outlook
Table 161 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 162 Recifarm AB: Product Benchmarking
Table 163 Recipharm AB: Strategic Outlook
Table 164 Waisman Biomanufacturing: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 165 Waisman Biomanufacturing: Product Benchmarking
Table 166 VGXI, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 167 VGXI, Inc. : Product Benchmarking
Table 168 VGXI Inc.: Strategic Outlook
Table 169 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 170 Batavia Biosciences B.V. : Product Benchmarking
Table 171 Batavia Biosciences B.V.: Strategic Outlook
Table 172 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 173 Wuxi AppTec: Product Benchmarking
Table 174 WuXi AppTec: Strategic Outlook
Table 175 ATUM: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 176 ATUM: Product Benchmarking
Table 177 ATUM: Strategic Outlook
Table 178 Altogen Biosystems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 179 Altogen Biosystems: Product Benchmarking
Table 180 Altogen Biosystems: Strategic Outlook
Table 181 Genezen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 182 Genezen: Product Benchmarking
Table 183 GENEZEN: Strategic Outlook
Table 184 SK pharmteco: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 185 SK pharmteco: Product Benchmarking
Table 186 SK pharmteco: Strategic Outlook
Table 187 Cytiva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 188 Cytiva: Product Benchmarking
Table 189 Cytiva: Strategic Outlook
Table 190 Virovek: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 191 Virovek : Product Benchmarking
Table 192 Virovek: Strategic Outlook
Table 193 Advanced BioScience Laboratories Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 194 Advanced BioScience Laboratories Inc.: Product Benchmarking
Table 195 Advanced BioScience Laboratories Inc.: Strategic Outlook
Table 196 3PBIOVIAN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 197 3PBIOVIAN: Product Benchmarking
Table 198 3PBIOVIAN: Strategic Outlook
Table 199 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 200 BioNTech SE: Product Benchmarking
Table 201 BioNTech SE: Strategic Outlook
Table 202 RegenxBio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 203 RegenxBio Inc.: Product Benchmarking
Table 204 Novartis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 205 Novartis: Product Benchmarking
Table 206 Novartis: Strategic Outlook
Table 207 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 208 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 209 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 210 Amicus Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 211 Amicus Therapeutics : Product Benchmarking
Table 212 Amicus Therapeutics: Strategic Outlook

List of Figures

Figure 1 Viral Vectors and Plasmid DNA Manufacturing Market Segmentation
Figure 2 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
Figure 3 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
Figure 4 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 5 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 6 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
Figure 7 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
Figure 8 Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index by Region
Figure 9 Viral Vectors and Plasmid DNA Manufacturing Market: Market Dynamics
Figure 10 Viral Vectors and Plasmid DNA Manufacturing Market: Impact Analysis
Figure 11 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 12 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 13 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 14 Short Term & Long Term Planning
Figure 15 Impact of U.S. and China Trade War
Figure 16 Most Impacted Countries
Figure 17 Viral Vectors and Plasmid DNA Manufacturing Market: Porter’s Five Forces Analysis
Figure 18 Viral Vectors and Plasmid DNA Manufacturing Market: PEST Analysis
Figure 19 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
Figure 20 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 21 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 22 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 23 Viral Vectors Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 24 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 25 Viral Vectors Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 26 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 27 Adeno-Associated Viruses (AAVs) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 28 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 29 Lentiviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 30 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 31 Adenoviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 32 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 33 Retroviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 34 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 35 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 36 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 37 Plasmid DNA Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 38 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
Figure 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 40 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025, 2030, 2035 (%)
Figure 41 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 42 Product Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 43 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 44 Services Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 45 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 46 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 47 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025, 2030, 2035 (%)
Figure 48 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 49 Downstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 50 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 51 Downstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 52 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 53 Purification Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 54 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 55 Fill Finish Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 56 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 57 Upstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 58 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 59 Upstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 60 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 61 Vector Amplification and Expansion Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 62 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 63 Vector Recovery/Harvesting Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 64 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 66 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025, 2030, 2035 (%)
Figure 67 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 68 Vaccine Development Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 69 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 70 Cell Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 71 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 72 Gene Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 73 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 74 Antisense & RNAi Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 75 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 76 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 77 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
Figure 78 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 79 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025, 2030, 2035 (%)
Figure 80 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 81 Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 82 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 83 Infectious Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 84 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 85 Genetic Disorders Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 86 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 87 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 88 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
Figure 89 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR %)
Figure 90 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-user, 2025, 2030, 2035 (%)
Figure 91 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 92 Biotechnology and Biopharmaceutical Companies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 93 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 94 CDMOs Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 95 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 96 Academics and Research Institutes Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 97 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 98 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 99 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025 and 2035 (Revenue, CAGR%)
Figure 100 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 101 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Billion, AGR %)
Figure 102 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 103 North America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 104 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 105 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 106 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 107 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 108 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 109 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 110 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 111 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 112 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 113 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 114 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 115 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 116 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 117 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 118 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 119 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 120 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 121 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 122 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 123 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 124 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 125 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 126 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 127 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 128 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 129 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 130 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 131 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 132 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 133 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 134 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 135 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 136 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 137 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 138 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 139 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 140 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 141 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 142 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 143 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 144 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 145 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 146 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 147 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 148 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 149 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 150 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 151 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 152 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 153 Russia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 154 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 155 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 156 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 157 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 158 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 159 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 160 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 161 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 162 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 163 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 164 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 165 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 166 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 167 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 168 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 169 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 170 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 171 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 172 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 173 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 174 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 175 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 176 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 177 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 178 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 179 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 180 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 181 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 182 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 183 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 184 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 185 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 186 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 187 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 188 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 189 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 190 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 191 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 192 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 193 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 194 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 195 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 196 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 197 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 198 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 199 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 200 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 201 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 202 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 203 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 204 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 205 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 206 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 207 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 208 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 209 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 210 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 211 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 212 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 213 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 214 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 215 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 216 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 217 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 218 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 219 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 220 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 221 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 222 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 223 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 224 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 225 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 226 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 227 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 228 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 229 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 230 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 231 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 232 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 233 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 234 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 235 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 236 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 237 Viral Vectors and Plasmid DNA Manufacturing Market: Company Share, 2024
Figure 238 Lonza Group Ltd.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 239 Lonza Group Ltd.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 240 Lonza Group: Regional Market Shares, 2024
Figure 241 Merck KGaA: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 242 Merck KGaA: R&D, 2020-2024 (US$ Million, AGR%)
Figure 243 Merck KGaA: Regional Market Shares, 2024
Figure 244 uniQure N.V.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 245 uniQure N.V.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 246 uniQure N.V.: Net Revenue: Business Market Shares, 2024
Figure 247 Catalent Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 248 Catalent Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 249 Catalent Inc.: Business Market Shares, 2024
Figure 250 Thermo Fisher Scientific Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 251 Thermo Fisher Scientific Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 252 Thermo Fisher Scientific Inc.: Regional Market Shares, 2024
Figure 253 Thermo Fisher Scientific Inc.: Business Market Shares, 2024
Figure 254 Charles River Laboratories: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 255 Charles River Laboratories International Inc: Regional Market Shares, 2024
Figure 256 bluebird bio Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 257 bluebird bio Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 258 VIVEbiotech: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 259 Recifarm AB: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 260 Wuxi AppTec: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 261 Wuxi AppTec: Regional Market Shares, 2024
Figure 262 Wuxi AppTec: Business Segment Market Shares, 2024
Figure 263 SK pharmteco: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 264 BioNTech SE: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 265 BioNTech SE: R&D, 2020-2024 (US$ Million, AGR%)
Figure 266 RegenxBio Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 267 RegenxBio Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 268 Novartis: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 269 Novartis: R&D, 2020-2024 (US$ Million, AGR%)
Figure 270 Novartis: Regional Market Shares, 2024
Figure 271 Novartis: Business Segment Market Shares, 2024
Figure 272 Boehringer Ingelheim International GmbH: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 273 Boehringer Ingelheim International GmbH: R&D, 2020-2024 (US$ Million, AGR%)
Figure 274 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
Figure 275 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2024
Figure 276 Amicus Therapeutics: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 277 Amicus Therapeutics: R&D, 2020-2024 (US$ Million, AGR%)

Companies Mentioned

3PBIOVIAN
Addgene
Advanced BioScience Laboratories Inc.
Aldevron
Altogen Biosystems
Amicus Therapeutics
ATUM
Batavia Biosciences B.V.
BioNTech SE
bluebird bio Inc.
Boehringer Ingelheim
Catalent Inc.
Charles River Laboratories
Creative Biogene
Cytiva
FUJIFILM Diosynth Biotechnologies
Genezen
Lonza Group Ltd.
Merck KGaA
Novartis
Recipharm AB
RegenxBio Inc
SK pharmteco
Thermo Fisher Scientific Inc.
uniQure N.V.
VGXI, Inc.
Virovek
VIVEbiotech
Waisman Biomanufacturing
Wuxi AppTec
2seventy bio
3P Biopharmaceuticals
3T Biosciences
4basebio PLC
AAVantgarde
AaviGen
ABL Europe SAS
Acuitas Therapeutics
AcuraBio
Adaptimmune LLC
ADLIN Science
Advanced Therapies Collaboration Center (ATxCC)
Afrigen Biologics
AGC Biologics
Alpha Teknova Inc.
Altaris LLC.
Andelyn Biosciences, Inc.
Anthos Therapeutics Inc.
AskBio
AstraZeneca
Aurigene Pharmaceutical Services
Autobahn Labs
Autolus Limited
Axovia Therapeutics
Ayrmid Pharma
Bavarian Nordic
Bayer
Belief BioMed
Bharat Biotech
Biogen
Biogeneric Pharma
BioMarin Pharmaceutical Inc
Bionova Scientific
Biotheus
Biovac Institute
BioVex, Inc.
Bristol Myers Squibb
Cellevate
CellTrans Inc.
Celularity Inc.
Circle Pharma
Dendreon Corp.
DNA Script
Dong-A ST Pharmaceutical
Dr. Reddy‚Äôs Laboratories
DualityBio
Duke University School of Medicine
Eleva
Enzyvant Therapeutics GmbH
Ethris
Eureka Therapeutics, Inc.
EVA Pharma
Exela Pharma Sciences
Ferring Pharmaceuticals
Fibrocell Technologies
Fuse Vectors
Galapagos NV
Gamida Cell Ltd.
Gamma Biosciences
Gene Therapy Research Institution Co. Ltd. (GTRI)
Genentech
Gilead
GSK
Halix B.V.
Humacyte Global, Inc.
Iovance Biotherapeutics, Inc.
Janssen Biotech, Inc.
Johnson & Johnson
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Kite Pharma, Inc.
Krystal Biotech, Inc.
Matica Biotechnology Inc.
Mesoblast, Inc.
Mirus Bio
Moderna
Navega Therapeutics
NecstGen
Nerio Therapeutics
Neurocrine Biosciences, Inc.
Neurotech Pharmaceuticals, Inc.
Novo Holdings A/S
Orchard Therapeutics (Europe) Limited
Pacira BioSciences Inc.
Pfizer Inc.
Pluristyx Inc.
PrexPharma
ProBio Inc.
PTC Therapeutics
Quantoom Biosciences
Roche Group
Sanofi
Sarapeta Therapeutics, Inc.
Sartorius
Spark Therapeutics, Inc.
Takara Bio
Takeda China
Vericel Corp.
Vertex Pharmaceuticals Incorporated
ViroCell
Vivet Therapeutics
Voyager Therapeutics, Inc.
WuXi AppTec
Advanced Research Projects Agency for Health (ARPA-H)
Africa CDC
African Vaccine Manufacturing Accelerator (AVMA)
American Society of Gene & Cell Therapy
Bespoke Gene Therapy Consortium (BGTC)
California Institute for Regenerative Medicine‚Äôs (CIRM)
Center for Biologics Evaluation and Research (CBER)
Center for Drug Evaluation (CDE)
Centers for Disease Control and Prevention (CDC)
Central Drugs Standard Control Organization (CDSCO)
Centre for Stem Cell Research (CSCR), Christian Medical College (CMC)
Charcot-Marie-Tooth Association (CMTA)
China's National Medical Products Administration (NMPA)
Committee for Advanced Therapies (CAT)
Council of Medical Research (ICMR)
Department of Biotechnology (DBT)
Egypt‚Äôs Government
Egypt‚Äôs Vaccine Biotechnology City (VBC)
European Medicines Agency (EMA)
European Union (EU)
FOXG1 Research Foundation (FRF)
French government
Gates Institute
Gavi, the African Union (AU)
Genetic Engineering Appraisal Committee (GEAC)
Harvard
Horizon Europe
IAVI
INADcure Foundation
Innovate UK
Institut Imagine
Institute for Protein Innovation (IPI)
Istituto Superiore di Sanit√† (ISS)
Japan‚Äôs Pharmaceuticals and Medical Devices Agency (PMDA)
Massachusetts Institute of Technology (MIT)
Medicines and Healthcare products Regulatory Agency (MHRA), UK
MEVAC
Mexican Government
Ministry of Health, Labour and Welfare (MHLW)
National Autonomous University of Mexico (UNAM)
National Research Council of Canada
National Scientific and Technical Research Council (CONICET)
New South Wales (NSW) Government
Office of Tissues and Advanced Therapies (OTAT)
Ragon Institute of Mass General
Regionalized Vaccine Manufacturing Collaborative (RVMC)
Review Committee on Genetic Manipulation (RCGM)
Royal Perth Hospital
San Raffaele Scientific Institute
Saudi Food and Drug Authority (SFDA)
Seattle Children‚Äôs Research Institute
South African Medical Research Council (SAMRC)
South Korea‚Äôs Ministry of Food and Drug Safety (MFDS)
Tecnol√≥gico de Monterrey
U.S. Food and Drug Administration (FDA)
UK Biobank
UMass Chan Medical School
University College London (UCL)
University of Colorado Anschutz Medical Campus
University of Colorado Anschutz Medical Campus
University of Manitoba
Uruguay‚Äôs Institut Pasteur de Montevideo
Vaccine Biotechnology City (VBC)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5347EUR$6,097USD£4,350GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6331EUR$7,218USD£5,150GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7437EUR$8,479USD£6,050GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9398EUR$10,714USD£7,645GBP